

1 What plays a role in the severity of Atopic Dermatitis in children?

2

3 1. Introduction

4 Atopic dermatitis (AD) is a chronic relapsing, pruritic, inflammatory skin disease [1].
5 This disorder is associated with many comorbid conditions leading to impaired
6 overall health and increased healthcare utilization [2]. It has been one of the most
7 common chronic diseases of the present time and affects 15 to 20 percent of the child
8 population worldwide [3]. The onset is most commonly observed at the age of 3 to 6
9 months, with approximately 60% of patients developing eczema in the first year of
10 their lives and 90% of patients by the age of 5 [1].

11 In order to prevent a disease that is remarkably common and has wide detrimental
12 effects, it is essential to determine the risk factors of the disease, however, the
13 pathogenesis of AD is not entirely understood [4].

14 With this single-centred cross-sectional study, we aimed at investigating the clinical
15 characteristics of pediatric patients with AD and identifying the factors associated
16 with the severity of the disease.

17 2. Materials and Methods

18 2.1. Clinical assessment

19 In our retrospective cross-sectional study, the data of the patients who applied
20 between December 2019 and December 2020 were obtained from the hospital
21 records. A total of 304 pediatric patients attending to Mardin State Hospital Pediatric
22 Allergy Outpatient Clinic between December 2019 and December 2020, and
23 diagnosed with AD according to Hanifin Rajka criteria [5, 6], at the time of admission
24 were included in this study. The individuals with a previous diagnosis of AD, with
25 dermographism, having dermatological diseases other than AD, under treatment, or
26 having a special diet were excluded.

27 The data on patients' age at admission, age at onset of symptoms, the presence of
28 atopy history in their family, the cigarette smoke exposure, and area of residence were
29 collected from the patients' records. Family history of atopy was defined as having at
30 least one parent or sibling with physician-diagnosed asthma, AD and/ or allergic
31 rhinitis [7].

1 Disease severity was determined according to the SCORAD index: The patients with
2 a score below 25 were classified as mild, 25-50 as moderate, and above 50 as severe
3 AD [8].

4 The eosinophil levels and eosinophil percentages were obtained from the complete
5 blood counts.

6 Epidermal prick tests (EPT) were performed on all of the patients. The panels
7 consisting of the 16 most common allergens in Turkey including food allergens
8 (cow's milk, egg white, egg yolk, wheat, hazelnut, peanut, soybean, fish species,
9 sesame, walnut) and aeroallergens (*Dermatophagoides farinae*, *Dermatophagoides*
10 *pteronyssunus*, *Alternaria tenuis*, *Penicillium notatum*, *Aspergillus fumigatus*) were
11 used for EPT [9]. Histamine was used as positive control while 0.9% NaCl solution as
12 negative control. The commercial extracts (brand name: Allergopharma; D-21462
13 Reinbek, Germany) were applied for EPT. The prick tests were performed to the volar
14 or dorsal of the forearms after cleaning the areas with alcohol and by using skin prick
15 test applicators (Medblue one 020013, Turkey). The wheal diameter that occurred 15
16 minutes after the tests had been applied was measured. The test was considered
17 positive if the wheal diameter was at least 3 mm greater compared to the negative
18 control [10]. Patients with positive results in EPT were accepted as "sensitized". All
19 epidermal prick tests were done and evaluated by the same clinician. Thus,
20 standardization was achieved in the application and evaluation of the tests.

21 The individuals found to be "sensitive" in the epidermal prick tests were undergone
22 oral food challenge (OFC) with the food allergen to which they were sensitive. Those
23 who had positive results in OFC were diagnosed with food allergy (FA).

24 The study protocol was approved by the Ethical Committee of Artuklu University,
25 Turkey. An informed written consent was obtained from the caregivers of the
26 participants.

27 **2.2.Statistical analyses**

28 Statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk,
29 NY). Results were indicated as means (standard deviations) for variables with a
30 normal distribution and as medians (interquartile range) for variables with skewed

1 distribution. The statistical significance of differences between the groups was tested
2 using the Chi-squared test and Fisher's exact test for categorical parameters; Mann-
3 Whitney U test and Kruskal-Wallis test for continuous parameters. Spearman's rank
4 correlation coefficients were assessed as measures of correlation between variables of
5 interest. To assess factors associated with SCORAD scores we applied linear
6 regression modeling. The variables that reach a p-value <0.10 in the univariate
7 analysis were included in a multiple linear regression analysis to investigate factors
8 independently associated with SCORAD scores. Values of $p <0.05$ were considered
9 to be statistically significant.

10 **3. Results**

11 A total of 304 pediatric patients with AD were enrolled in the study. The mean age at
12 admission was 8.1 (± 4.8) months and the mean age at the onset of symptoms was 4.5
13 (± 3) months. There was a slight male predominance in the whole study group (64%
14 male, 36% female).

15 The median SCORAD score of the whole study group was 16 (IQR: 13-24).
16 According to the classification of AD severity, 75.3% (229) of the patients had mild,
17 20.4% (62) had moderate, and 4.3% (13) had severe AD.

18 The ages at admission and at the onset of the symptoms were significantly lower in
19 patients with severe and moderate disease than the patients with mild disease
20 ($p=0.009$, $p<0.001$) (**Table 1**). There was a negative correlation between the
21 SCORAD score and both age at admission ($r=-0.277$, $p<0.001$) and age at onset of the
22 symptoms ($r=-0.474$, $p<0.001$) (**Figure 1**). Any significant relationship between the
23 severity of disease and gender were not observed (**Table 1**).

24 While 38% of the whole study group had FA, this rate was 23.1% in mild cases and
25 90.7% in moderate and severe cases (**Table 1**). Food sensitization rates were higher in
26 individuals with moderate and severe disease ($p<0.001$) and patients with FA had
27 significantly higher SCORAD scores [33 (IQR: 22-44) vs 14 (IQR: 12-16); $p<0.001$]
28 (**Figure 2a**). Furthermore, the median age at the onset of AD symptoms was
29 significantly lower for individuals with FA than the ones without FA [5(IQR: 2-4) vs
30 2 (IQR: 3-7); $p<0.001$]. Egg and milk were the leading foods to which the patients
31 were sensitive (**Figure 3**).

1 The majority of severely affected patients were living in rural areas (**Table 1**) and
2 concerning the whole study group, it was observed that the ones living in rural areas
3 had higher SCORAD scores than the individuals living in urban areas [22 (IQR: 15-
4 39.5) vs 15(IQR:12-22); $p<0.001$] (**Figure 2b**).

5 The frequency of familial atopy was 29.6% and significantly higher in the ones with
6 moderate and severe disease than the mild disease (66.5% vs 17.5%; $p<0.001$) (**Table**
7 **1**). Moreover, the SCORAD scores of the patients with familial atopy history were
8 notably higher (35.5(IQR: 21.75-46) vs 14 (IQR:12-19); $p<0.001$) (**Figure 2c**).

9 Sixty-five per cent of the patients in the entire study group were exposed to passive
10 cigarette smoking. The frequency of tobacco exposure was remarkably higher in
11 severe and moderate patients than mild patients (90.7% vs. 56.8%; $p<0.001$) (**Table**
12 **1**). Likewise, SCORAD scores were higher in patients exposed to passive cigarette
13 smoking [21(IQR:14.75-38) vs. 13(IQR:12-16); $p<0.001$] (**Figure 2d**).

14 The eosinophil count and peripheral eosinophil percentages were significantly higher
15 in severe and moderate cases than mild ones [630(IQR: 450-850) / μ l vs. 170(IQR: 80-
16 405) / μ l; $p<0.001$ and 49(IQR:31-65)% vs. 11(IQR:2-33.5) %; $p<0.001$] (**Table 1**).
17 Both the eosinophil count and percentage found to be positively correlated with
18 SCORAD scores ($r=0.531$, $p<0.001$ and $r=0.434$, $p<0.001$) (**Figure 4**).

19 In the multi-regression analysis, we observed that earlier onset of symptoms, having
20 familial atopy, FA, and higher eosinophil counts were independently **associated** with
21 SCORAD scores (**Table 2**).

22 **4. Discussion**

23 In the present study, we assessed the factors associated with the severity of AD in
24 children. Patients with earlier onset of the symptoms, food sensitivity, positive
25 familial history for atopy, rural area of residence, cigarette smokes exposure, higher
26 blood eosinophil levels were found to be more prone to have severe AD.

27 We analyzed the severity of AD in our patients by SCORAD index, which has been
28 reported as one of the most reliable and practicable methods [8, 11]. One fourth of the
29 participants in this study were moderate-severe cases. This rate is lower than what is

1 reported in the former study by Ricci et al [12], which was performed in a pediatric
2 population with a similar number of cases. The previous studies conducted on
3 pediatric AD patients in Turkey have also reported larger proportions of severe cases
4 [13-15]. In the UK, however, the rates of mild, moderate, and severe AD in children
5 reported to be 82, 12, and 6%, respectively; which are comparable to our results [16].
6 Hence, these differences could be attributed to variations in methodology and
7 populations.

8 The ratio of mild to severe AD patients likely increases with age [16]. In our study,
9 the individuals showing symptoms at an earlier age had higher SCORAD scores, and
10 the median age of the severe-moderate cases was found to be lower than the mild
11 cases. The regression analysis revealed that younger age was an independent factor
12 associated with a more severe clinical picture in AD. Therefore, cases with early onset
13 of AD symptoms should be monitored more closely due to a high possibility of a
14 severe and persistent clinical course.

15

16 Although some studies report slightly female predominance [17,18], the majority of
17 the patients, particularly those with severe disease were male in our study population.
18 Besides, in consistency with the former studies [19], we couldn't reveal any
19 significant relations between the severity of AD and patient's gender.

20

21 FA can coexists with AD in infancy [20]. In two-fifths of our patients, AD is
22 accompanied by food sensitivity and consistent with the literature [16], egg and milk
23 sensitivity were the most common triggers prevalent. Almost all of our moderate and
24 severe cases had FA. These results were similar to previous studies, suggesting that in
25 the first two years of life, the majority of infants with moderate to severe disease
26 shows sensitization to food allergens, whereas those with mild disease are less
27 sensitized [21,22]. In a retrospective study, it was observed that the patients with FA
28 developed AD at earlier ages [23]. Similar to this study, we revealed that AD
29 symptoms appeared earlier in the cases accompanied by FA, and severity scores of
30 these cases were significantly higher than the ones without FA.

31 Recently the prevalence and incidence of AD have been increasing. A major theory
32 explaining this trend, in general, is the 'hygiene hypothesis' that supports an inverse

1 relationship between AD and exposure to endotoxin, early daycare, farm animal, and
2 dog pets in early life [24,25]. As part of the ‘hygiene hypothesis,’ it has been thought
3 that AD is more common in urban than in rural communities [26]. In the context of
4 this hypothesis, we analyzed the association between the area of residence and the
5 severity of AD. Contrary to the previous studies, we found that the individuals living
6 in rural areas had higher SCORAD scores than the ones living in urban areas.
7 Longitudinal cohort studies conducted in this particular region of Turkey are needed
8 to explain this difference and reveal any causation.

9

10 Population-based studies have indicated that the strongest risk factor is a positive
11 family history for atopic diseases, particularly for AD [27]. Approximately 70 percent
12 of individuals with AD have a positive family history of atopic diseases [28]. Patients
13 with one atopic parent have two to threefold increased risk of developing AD.
14 Moreover the risk increases to three to fivefold in case both parents are atopic [1]. In
15 our study, almost all of the severe cases had a positive family history of atopic
16 diseases. The SCORAD scores of the patients with familial atopy history were
17 significantly higher. We can postulate that positive family history for atopic diseases
18 increases the possibility of a more severe clinical course for patients with AD.

19 Early studies have shown that cigarette smoke in the environment increases children’s
20 risk of allergic sensitization [29]. A meta-analysis reviewed 86 studies, from 39
21 countries, investigated the association of active smoking, passive smoking exposure,
22 and maternal smoking during pregnancy with childhood AD, and concluded that
23 childhood AD was significantly associated with passive smoking exposure [30]. In
24 our study, 90.7% of severe and moderate cases had passive cigarette smoking
25 exposure and those with passive cigarette smoking exposure had a significantly higher
26 SCORAD score. These results indicate that passive tobacco exposure increases the
27 severity of AD. Therefore, it is strongly recommended that all caregivers should stop
28 smoking.

29 Eosinophilia in patients with AD is usually mentioned as a nonspecific finding [31].
30 However, recent studies have determined a positive correlation between peripheral
31 eosinophilia and the severity of AD [13,32]. Comparable to these studies, we found
32 that the blood eosinophil count and the eosinophil percentage of moderate and severe

1 cases were higher than mild cases. Besides, a positive correlation was established
2 between patients' SCORAD scores and the eosinophil counts and percentages. Since
3 they can be practically evaluated and have potential utility in clinical practice; blood
4 eosinophil count and percentage can be very valuable parameters for assessing the
5 severity of AD in children.

6 As far as we know, this study was one of the few studies evaluating children with AD
7 in this particular region of Turkey. Because of the **retrospective cross-sectional** nature
8 and relatively small sample size of our study, our findings on investigating possible
9 factors associated with the increased severity of AD were limited. Especially, the
10 socioeconomic or cultural level of the patients, that may affect the parameters (such
11 as passive cigarette smoking, living in rural areas) that we consider in assessing the
12 severity of AD could not be evaluated within the scope of our study. Further studies
13 are still needed to clarify the factors playing a role in severe AD in the pediatric
14 population.

15

16 **5. Conclusion**

17 Our findings show that early-onset, food sensitivity, having familial atopy history and
18 passive smoke exposure play a significant role in severe AD, consistent with the
19 previous reports. On the contrary, living in rural areas was found to be associated with
20 severe AD. Since it is remarkably correlated with SCORAD scores, we can postulate
21 that eosinophil count can be used as a marker to assess the severity of AD in children.

22

23

24

25

26

27

28

1 6. References

- 2
3 1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, et al.
4 Guidelines of care for the management of atopic dermatitis: section 1.
5 Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol* 2014; 70
6 (2): 338-351. doi: 10.1016/j.jaad.2013.10.010.
- 7 2. Silverberg JI, Simpson EL. Association between severe eczema in children
8 and multiple comorbid conditions and increased healthcare utilization. *Pediatr*
9 *Allergy Immunol.* 2013; 24 (5): 476-86. doi: 10.1111/pai.12095.
- 10 3. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK,
11 Williams H; ISAAC Phase Three Study Group. Worldwide time trends in the
12 prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in
13 childhood: ISAAC Phases One and Three repeat multicountry cross-sectional
14 surveys. *Lancet.* 2006; 368 (9537): 733-43. doi: 10.1016/S0140-
15 6736(06)69283-0.
- 16 4. Kapur S, Watson W, Carr S. Atopic dermatitis. *Allergy Asthma Clin*
17 *Immunol.* 2018; 14 (Suppl 2): 52. doi: 10.1186/s13223-018-0281-6.
- 18 5. Hanifin, J. Diagnostic features of atopic eczema. *Acta Dermatol Venereol*
19 (Stockh) 1980; 60 (92): p. 44-47. doi : 10.2340/00015555924447.
- 20 6. Vakharia PP, Chopra R, Silverberg JI. Systematic Review of Diagnostic
21 Criteria Used in Atopic Dermatitis Randomized Controlled Trials. *Am J Clin*
22 *Dermatol* 2018; 19 (1): 15-22. doi: 10.1007/s40257-017-0299-4.
- 23 7. Böhme M, Wickman M, Lennart Nordvall S, Svartengren M, Wahlgren C.
24 Family history and risk of atopic dermatitis in children up to 4 years. *Clinical*

- 1 & Experimental Allergy. 2003;33(9):1226-31.doi: 10.1046/j.1365-
2 2222.2003.01749.x.
- 3 8. Ertam I, Su O, Alper S, Sarıcaoglu H, Karadağ AS, et al. The Turkish
4 guideline for the diagnosis and management of atopic dermatitis-2018.
5 TURKDERM-Turkish Archives of Dermatology and Venereology 2018.
6 **52**(1): p. 6-23. doi: 10.4274/turkderm.87143.
- 7 9. Kahveci M, Koken G, Şahiner ÜM, Soyer Ö, Şekerel BE. Immunoglobulin E-
8 Mediated Food Allergies Differ in East Mediterranean Children Aged 0-2
9 Years. *Int Arch Allergy Immunol* 2020; 181 (5): 365-374. doi:
10 10.1159/000505996.
- 11 10. Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, et al. The
12 skin prick test - European standards. *Clin Transl Allergy* 2013; 3 (1): 3. doi:
13 10.1186/2045-7022-3-3.
- 14 11. Oranje AP. Practical issues on interpretation of scoring atopic dermatitis:
15 SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-
16 Item Severity score. *Curr Probl Dermatol* 2011; 41: 149-155. doi:
17 10.1159/000323308.
- 18 12. Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, et al. Long-term follow-up
19 of atopic dermatitis: retrospective analysis of related risk factors and
20 association with concomitant allergic diseases. *J Am Acad Dermatol* 2006; 55
21 (5): 765-771. doi: 10.1016/j.jaad.2006.04.064.
- 22 13. Akan A, Azkur D, Civelek E, Erkoçoğlu M, Yılmaz-Öztorun Z, et al. Risk
23 factors of severe atopic dermatitis in childhood: single-center experience. *Turk*
24 *J Pediatr* 2014; 56 (2):121-126.

- 1 14. Ozceker D, Bulut M, Ozbay AC, Dilek F, Koser M, et al. Assessment of IL-31
2 levels and disease severity in children with atopic dermatitis. *Allergol*
3 *Immunopathol (Madr)* 2018; 46 (4): 322-325. doi:
4 10.1016/j.aller.2017.10.005.
- 5 15. Su O, Bahalı AG, Demir AD, Ozkaya DB, Uzuner S, et al. The relationship
6 between severity of disease and vitamin D levels in children with atopic
7 dermatitis. *Postepy Dermatol Alergol* 2017; 34 (3): 224-227. doi:
8 10.5114/pdia.2017.66054.
- 9 16. Huang E, Ong PY. Severe Atopic Dermatitis in Children. *Curr Allergy*
10 *Asthma Rep* 2018; 18 (6): 35. doi: 10.1007/s11882-018-0788-4.
- 11 17. Larsen, F.S. and J.M. Hanifin, Epidemiology of atopic dermatitis.
12 *Immunology and Allergy Clinics of North America* 2002; 22 (1): 1-24. doi :
13 10.1016/S0889-8561(03)00066-3.
- 14 18. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, et al.
15 Worldwide variations in the prevalence of symptoms of atopic eczema in the
16 International Study of Asthma and Allergies in Childhood. *J Allergy Clin*
17 *Immunol.* 1999; 103 (1 Pt 1): 125-38. doi: 10.1016/s0091-6749(99)70536-1.
- 18 19. Ballardini N, Kull I, Söderhäll C, Lilja G, Wickman M, et al. Eczema severity
19 in preadolescent children and its relation to sex, filaggrin mutations, asthma,
20 rhinitis, aggravating factors and topical treatment: a report from the BAMSE
21 birth cohort. *Br J Dermatol* 2013; 168 (3): 588-594. doi: 10.1111/bjd.12196.
- 22 20. Yang L, Fu J, Zhou Y. Research Progress in Atopic March. *Front Immunol*
23 2020; 11: 1907. doi: 10.3389/fimmu.2020.01907.

- 1 21. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, et al. The natural course of
2 atopic dermatitis from birth to age 7 years and the association with asthma. *J*
3 *Allergy Clin Immuno* 2004; 113 (5): 925-931. doi: 10.1016/j.jaci.2004.01.778.
- 4 22. De Benedictis FM, Franceschini F, Hill D, Naspitz C, Simons FE, et al. The
5 allergic sensitization in infants with atopic eczema from different countries.
6 *Allergy* 2009; 64 (2): 295-303. doi: 10.1111/j.1398-9995.2008.01779.x.
- 7 23. Kijima A, Murota H, Takahashi A, Arase N, Yang L, et al. Prevalence and
8 impact of past history of food allergy in atopic dermatitis. *Allergol Int* 2013;
9 62 (1): 105-112. doi: 10.2332/allergolint.12-OA-0468.
- 10 24. Flohr C, Pascoe D, Williams HC. Atopic dermatitis and the 'hygiene
11 hypothesis': too clean to be true? *Br J Dermatol* 2005; 152 (2): 202-216. doi:
12 10.1111/j.1365-2133.2004.06436.x.
- 13 25. Flohr, C. and L. Yeo, Atopic dermatitis and the hygiene hypothesis revisited,
14 in *Pathogenesis and Management of Atopic Dermatitis*. 2011, Karger
15 Publishers. p. 1-34. doi: [10.1159/000323290](https://doi.org/10.1159/000323290).
- 16 26. Schram ME, Tedja AM, Spijker R, Bos JD, Williams HC, et al. Is there a
17 rural/urban gradient in the prevalence of eczema? A systematic review. *Br J*
18 *Dermatol* 2010; 162 (5): 964-973. doi: 10.1111/j.1365-2133.2010.09689.x.
- 19 27. Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population-
20 based cross-sectional study in Germany. *Allergy* 2011; 66 (2): 206-213. doi:
21 10.1111/j.1398-9995.2010.02464.x.
- 22 28. Wen HJ, Chen PC, Chiang TL, Lin SJ, Chuang YL, et al. Predicting risk for
23 early infantile atopic dermatitis by hereditary and environmental factors. *Br J*
24 *Dermatol* 2009; 161 (5): 1166-1172. doi: 10.1111/j.1365-2133.2009.09412.x.

- 1 29. Lannerö E, Wickman M, van Hage M, Bergström A, Pershagen G, et al.
2 Exposure to environmental tobacco smoke and sensitisation in children.
3 Thorax 2008; 63 (2): 172-176. doi: 10.1136/thx.2007.079053.
- 4 30. Kantor R, Silverberg JI. Environmental risk factors and their role in the
5 management of atopic dermatitis. Expert review of clinical immunology.
6 2017;13(1):15-26. doi: 10.1080/1744666X.2016.1212660.
- 7 31. Bieber, T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494. doi:
8 10.1056/NEJMra074081.
- 9 32. Özdoğru EE, Gönülal M. Atopic dermatitis, inhalant allergy and food allergy:
10 A paediatric approach. Dermatol Ther 2020: e14542. doi: 10.1111/dth.14542.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

- 1 **Table1.** Comparison of the clinical and laboratory characteristics of patients in order
- 2 to AD severity

	Mild (n=229)	Moderate & Severe (n=75)	<i>p value</i>
Age at admission (<i>months</i>)	7 (IQR: 5-11)	6 (IQR: 4-7)	0.009
Age at the onset of symptoms (<i>months</i>)	4 (IQR: 2.5-6)	2 (IQR: 1-3)	<0.001
Gender of the patients (Male/Female) [<i>n (%)</i>]/ <i>n (%)</i>]	144 (62.9) /85 (37.1)	51 (68)/24 (32)	0.42
Patients with food allergy [<i>n (%)</i>]	53 (23.1)	68 (90.7)	<0.001
Patients living in rural areas [<i>n (%)</i>]	56 (24.5)	37 (49.3)	<0.001
Family history of atopy [<i>n (%)</i>]	40 (17.4)	50 (66.7)	<0.001
Cigarette smoke exposure [<i>n (%)</i>]	130 (56.8)	68 (90.7)	<0.001
Eosinophil count (μ l)	170 (IQR: 80-405)	630(IQR: 450-850)	<0.001
Peripheral eosinophil percentage (%)	11(IQR: 2-33.5)	49 (IQR: 31-65)	<0.001

Abbreviations: Values in table are presented as the number of patients with/without the percentage in parenthesis, as the median with the interquartile range (IQR) in parenthesis as appropriate

- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10

1 **Table 2.** Linear regression analysis of factors associated with greater SCORAD
 2 scores
 3

Table 2. Linear regression analysis of factors associated with greater SCORAD scores

	Univariate linear regression			Multiple linear regression		
	B coefficient	95% CI	p	B coefficient	95% CI	p
Age at the onset of symptoms	-0.396	-1.93 to -1.045	<0.001	-0.74	-0.58 to -0.01	0.04
Food allergy	0.74	17.76 to 21.75	<0.001	0.50	11.1 to 15.54	<0.001
Gender	-0.04	-4.10 to 2.01	0.5			
Region of residency	-0.26	-10.93 to -4.39	<0.001	-0.05	-3.40 to 0.49	0.14
Family history of atopy	0.54	7.28 to -10.41	<0.001	0.20	3.42 to 7.98	<0.001
Cigarette smoke exposure	0.38	7.62 to 13.3	<0.001	0.04	-0.80 to 3.20	0.23
Eosinophil count	0.54	0.011 to 0.015	<0.001	0.27	0.005 to 0.008	<0.001

Abbreviations: SCORAD, Scoring Atopic Dermatitis Index, CI: coefficient interval

4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25


1 **Figure Legends**

2 **Figure 1.** Correlation between the SCORAD score and age [(a) at admission and (b)


3 at the onset of the symptoms] (r , Spearman's rank correlation)

4

a. 5
6




b.



7

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31


1 **Figure 2.** Comparison of SCORAD scores of patients in the context of (a) food
2 allergy, (b) the area of residence, (c) family history of atopy and (d) passive smoke
3 exposure.



23

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



1 **Figure 3.** Distribution of the frequency of food sensitivity in patients according to the
2 food type



16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1 **Figure 4** . Correlation between SCORAD scores and (a) the eosinophil count , (b)
2 peripheral (r , Spearman's rank correlation)

3
4



5

6
7
8
9